These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 24710841)
21. Active metabolite concentration of clopidogrel in patients taking different doses of aspirin: results of the interaction trial. Liang Y; Hirsh J; Weitz JI; Sloane D; Gao P; Pare G; Zhu J; Eikelboom JW J Thromb Haemost; 2015 Mar; 13(3):347-52. PubMed ID: 25557828 [TBL] [Abstract][Full Text] [Related]
22. The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers. Umemura K; Iwaki T Clin Pharmacol Drug Dev; 2016 Nov; 5(6):480-487. PubMed ID: 27514617 [TBL] [Abstract][Full Text] [Related]
23. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 genotype in patients with high on-treatment reactivity. Barker CM; Murray SS; Teirstein PS; Kandzari DE; Topol EJ; Price MJ JACC Cardiovasc Interv; 2010 Oct; 3(10):1001-7. PubMed ID: 20965456 [TBL] [Abstract][Full Text] [Related]
24. Impacts of CYP2C19 genetic polymorphisms on bioavailability and effect on platelet adhesion of vicagrel, a novel thienopyridine P2Y Zhang Y; Zhu X; Zhan Y; Li X; Liu C; Zhu Y; Zhang H; Wei H; Xia Y; Sun H; Liu Y; Lai X; Gong Y; Liu X; Li Y; Ding Y; Zhong D Br J Clin Pharmacol; 2020 Sep; 86(9):1860-1874. PubMed ID: 32267573 [TBL] [Abstract][Full Text] [Related]
25. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping. Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219 [TBL] [Abstract][Full Text] [Related]
26. Effects of individualized antiplatelet therapy based on CYP2C19 genotype and platelet function on the prognosis of patients after PCI. Zhang M; Wang JR; Zhang Y; Zhang P; Ren MY; Jia XM; Ma LP; Gao M; Hou YL Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10753-10768. PubMed ID: 33155236 [TBL] [Abstract][Full Text] [Related]
27. CYP2C19 but not PON1 genetic variants influence clopidogrel pharmacokinetics, pharmacodynamics, and clinical efficacy in post-myocardial infarction patients. Hulot JS; Collet JP; Cayla G; Silvain J; Allanic F; Bellemain-Appaix A; Scott SA; Montalescot G Circ Cardiovasc Interv; 2011 Oct; 4(5):422-8. PubMed ID: 21972404 [TBL] [Abstract][Full Text] [Related]
28. Prediction of clopidogrel low responders by a rapid CYP2C19 activity test. Tazaki J; Jinnai T; Tada T; Kato Y; Makiyama T; Ikeda T; Yamane K; Naruse Y; Takahashi K; Watanabe H; Kimura T; Horiuchi H J Atheroscler Thromb; 2012; 19(2):186-93. PubMed ID: 22166969 [TBL] [Abstract][Full Text] [Related]
29. Correlation between the CYP2C19 phenotype status and the results of three different platelet function tests in cardiovascular disease patients receiving antiplatelet therapy: an emphasis on newly introduced platelet function analyzer-200 P2Y test. Li S; Choi JL; Guo LZ; Goh RY; Kim BR; Woo KS; Kim MH; Han JY Ann Lab Med; 2016 Jan; 36(1):42-8. PubMed ID: 26522758 [TBL] [Abstract][Full Text] [Related]
30. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717 [TBL] [Abstract][Full Text] [Related]
31. CYP2C19 polymorphisms and coronary heart disease risk factors synergistically impact clopidogrel response variety after percutaneous coronary intervention. Liu T; Yin T; Li Y; Song LQ; Yu J; Si R; Zhang YM; He Y; Guo WY; Wang HC Coron Artery Dis; 2014 Aug; 25(5):412-20. PubMed ID: 24608794 [TBL] [Abstract][Full Text] [Related]
32. Non-antiplatelet effect of clopidogrel: improving endothelial function in Chinese healthy subjects with different CYP2C19 genotype. Zhang YZ; Chen BL; Zhang W; Cao X Clin Exp Pharmacol Physiol; 2015 Jan; 42(1):22-6. PubMed ID: 25311974 [TBL] [Abstract][Full Text] [Related]
33. Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study. Gladding P; White H; Voss J; Ormiston J; Stewart J; Ruygrok P; Bvaldivia B; Baak R; White C; Webster M JACC Cardiovasc Interv; 2009 Nov; 2(11):1095-101. PubMed ID: 19926050 [TBL] [Abstract][Full Text] [Related]
34. CYP2C19*17 increases clopidogrel-mediated platelet inhibition but does not alter the pharmacokinetics of the active metabolite of clopidogrel. Pedersen RS; Nielsen F; Stage TB; Vinholt PJ; el Achwah AB; Damkier P; Brosen K Clin Exp Pharmacol Physiol; 2014 Nov; 41(11):870-8. PubMed ID: 25115434 [TBL] [Abstract][Full Text] [Related]
35. Impact of CYP2C19 Metabolizer Status on Patients With ACS Treated With Prasugrel Versus Clopidogrel. Doll JA; Neely ML; Roe MT; Armstrong PW; White HD; Prabhakaran D; Winters KJ; Duvvuru S; Sundseth SS; Jakubowski JA; Gurbel PA; Bhatt DL; Ohman EM; Fox KAA; J Am Coll Cardiol; 2016 Mar; 67(8):936-947. PubMed ID: 26916483 [TBL] [Abstract][Full Text] [Related]
36. Physiologically based pharmacokinetic modeling for sequential metabolism: effect of CYP2C19 genetic polymorphism on clopidogrel and clopidogrel active metabolite pharmacokinetics. Djebli N; Fabre D; Boulenc X; Fabre G; Sultan E; Hurbin F Drug Metab Dispos; 2015 Apr; 43(4):510-22. PubMed ID: 25609219 [TBL] [Abstract][Full Text] [Related]
37. Influence of CYP2C19 loss-of-function variants on the metabolism of clopidogrel in patients from north-western China. Lin R; Zhang L; Zhang P; Zhou L; Liu T; Li Y; Zhang W; Wang W; Zhang J J Clin Pharm Ther; 2015 Jun; 40(3):308-14. PubMed ID: 25810245 [TBL] [Abstract][Full Text] [Related]
38. Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan. Jinnai T; Horiuchi H; Makiyama T; Tazaki J; Tada T; Akao M; Ono K; Hoshino K; Naruse Y; Takahashi K; Watanabe H; Kita T; Kimura T Circ J; 2009 Aug; 73(8):1498-503. PubMed ID: 19531897 [TBL] [Abstract][Full Text] [Related]
39. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858 [TBL] [Abstract][Full Text] [Related]
40. Prevention of gastric mucosal injury induced by anti-platelet drugs by famotidine. Uotani T; Sugimoto M; Nishino M; Ichikawa H; Sahara S; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Watanabe H; Miyajima H; Furuta T J Clin Pharmacol; 2014 Aug; 54(8):858-64. PubMed ID: 24615745 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]